Scarica l'app Stockscreener
0.635
4.73%
0.0287
Dopo l'orario di chiusura:
.60
-0.035
-5.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - MarketScreener
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech redesigns cancer trial to seek faster FDA approval - Stock Titan
PDS Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotechnology to announce Q4 and full year results on March 30 with clinical and corporate update - tradersunion.com
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
PDS Biotech pairs 2025 results with a clinical update on March 30 - Stock Titan
PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday - Defense World
Will PDS Biotechnology Corporation stock go up in YEARPortfolio Profit Report & Safe Entry Momentum Tips - baoquankhu1.vn
Block Trades: Can PDS Biotechnology Corporation stock outperform in a bear market2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
PDSB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology grants 300,000 options to executive | PDSB SEC FilingForm 4 - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
PDS Biotechnology director granted 54,876 options | PDSB SEC FilingForm 4 - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com Australia
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
PDSB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
PDS Biotech (NASDAQ: PDSB) highlights HPV16 trial gains and pipeline - Stock Titan
Will PDS Biotechnology Corporation stock outperform Dow Jones indexMarket Movers & Consistent Profit Focused Trading Strategies - mfd.ru
PDS Biotechnology Amends Late-Stage Trial for PDS0101 to Support Accelerated Approval Pathway in HPV16-Positive Head and Neck Cancer - marketscreener.com
PDS Biotech amends Phase 3 trial to add accelerated approval path - Investing.com
LiveRamp Holdings, Inc. has announced a partnership with Scowtt - Bitget
Nucor has announced that Jack Sullivan has been promoted to Chief Financial Officer, Treasurer, and Executive Vice President of the company. - Bitget
PDS Biotechnology Corporation (PDS Biotech) recently announced that it has made significant amendments to the study protocol of its Phase III clinical trial, Versatile-003. - Bitget
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - The Manila Times
Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients - Stock Titan
Published on: 2026-02-19 10:39:09 - baoquankhu1.vn
PDS Biotechnology Approaches Critical Regulatory and Clinical Milestones - AD HOC NEWS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):